Physician profile
Mohammad Khan
NPI 1669026019
$2,814.20
in general payments reported to CMS, 2019-2025
23 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.01 · 2022: $219 · 2023: $439 · 2024: $699 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.07 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $574.26 | 2023-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $411.32 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $298.04 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $259.46 | 2025 | |
| Ucb, INC. | $198.62 | 2024-2025 | Bimzelx |
| Shionogi INC | $163.71 | 2022-2023 | Fetroja |
| Glaxosmithkline, LLC. | $130.37 | 2023-2025 | Benlysta |
| Celgene Corporation | $112.48 | 2022-2025 | Reblozyl |
| Insmed, INC. | $107.44 | 2022-2024 | Arikayce |
| Janssen Biotech, INC. | $92.57 | 2024-2025 | Tremfya |
| Sobi, INC | $90.60 | 2025 | |
| Genentech USA, INC. | $84.32 | 2022-2023 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.24 | 2023 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $34.44 | 2025 | |
| Mallinckrodt Hospital Products INC. | $29.96 | 2023 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $24.44 | 2025 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $24.28 | 2025 | Lupkynis |
| Novo Nordisk INC | $21.82 | 2024 | Wegovy |
| Pfizer INC. | $21.01 | 2021 | |
| Pharmacosmos Therapeutics INC. | $19.17 | 2025 | Monoferric |
| Fresenius Kabi USA, LLC | $18.73 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $17.16 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.